Larry Norton

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kirchhoff Tomas; Chen Zhang-qun; Gold Bert; Pal Prodipto; Gaudet Mia M; Kosarin Kristi; Levine Douglas A; Gregersen Peter; Spencer Sara; Harlan Megan; Robson Mark; Klein Robert J; Hudis Clifford A; Norton Larry; Dean Michael; Offit Kenneth
The 6q22.33 locus and breast cancer susceptibility.
Zhang Xiang H-F; Wang Qiongqing; Gerald William; Hudis Clifford A; Norton Larry; Smid Marcel; Foekens John A; Massagué Joan
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Sugarman Steven; Wasserheit Carolyn; Hodgman Elizabeth; Coglianese Maryellen; D'Alassandro Anne; Fournier Monica; Troso-Sandoval Tiffany; D'Andrea Gabriella; Drullinsky Pamela; Lake Diana; George Roshini; Mills Nancy; Moynahan Maryellen; Smith Joyce; Panageas Katherine; Norton Larry; Hudis Clifford
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Larry Norton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kirchhoff Tomas; Chen Zhang-qun; Gold Bert; Pal Prodipto; Gaudet Mia M; Kosarin Kristi; Levine Douglas A; Gregersen Peter; Spencer Sara; Harlan Megan; Robson Mark; Klein Robert J; Hudis Clifford A; Norton Larry; Dean Michael; Offit Kenneth
The 6q22.33 locus and breast cancer susceptibility.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(9):2468-75.
2009: Zhang Xiang H-F; Wang Qiongqing; Gerald William; Hudis Clifford A; Norton Larry; Smid Marcel; Foekens John A; Massagué Joan
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Cancer cell 2009;16(1):67-78.
2009: Sugarman Steven; Wasserheit Carolyn; Hodgman Elizabeth; Coglianese Maryellen; D'Alassandro Anne; Fournier Monica; Troso-Sandoval Tiffany; D'Andrea Gabriella; Drullinsky Pamela; Lake Diana; George Roshini; Mills Nancy; Moynahan Maryellen; Smith Joyce; Panageas Katherine; Norton Larry; Hudis Clifford
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Breast cancer research and treatment 2009;115(3):609-12.
2009: Muss Hyman B; Berry Donald A; Cirrincione Constance T; Theodoulou Maria; Mauer Ann M; Kornblith Alice B; Partridge Ann H; Dressler Lynn G; Cohen Harvey J; Becker Heather P; Kartcheske Patricia A; Wheeler Judith D; Perez Edith A; Wolff Antonio C; Gralow Julie R; Burstein Harold J; Mahmood Ahmad A; Magrinat Gustav; Parker Barbara A; Hart Ronald D; Grenier Debjani; Norton Larry; Hudis Clifford A; Winer Eric P;
Adjuvant chemotherapy in older women with early-stage breast cancer.
The New England journal of medicine 2009;360(20):2055-65.
2009: Kimmick G G; Cirrincione C; Duggan D B; Bhalla K; Robert N; Berry D; Norton L; Lemke S; Henderson I C; Hudis C; Winer E;
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Breast cancer research and treatment 2009;113(3):479-90.
2008: Dickler Maura N; Rugo Hope S; Eberle Carey A; Brogi Edi; Caravelli James F; Panageas Katherine S; Boyd Jeff; Yeh Benjamin; Lake Diana E; Dang Chau T; Gilewski Teresa A; Bromberg Jacqueline F; Seidman Andrew D; D'Andrea Gabriella M; Moasser Mark M; Melisko Michele; Park John W; Dancey Janet; Norton Larry; Hudis Clifford A
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7878-83.
2008: Dang Chau; D'Andrea Gabriella; Lake Diana; Sugarman Steve; Fornier Monica; Moynahan Mary Ellen; Gilewski Theresa; Hurria Arti; Mills Nancy; Troso-Sandoval Tiffany; George Roshini; Robson Mark; Dickler Maura; Smith Karen; Panageas Katherine S; Norton Larry; Hudis Clifford A
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
Clinical breast cancer 2008;8(5):418-24.
2008: Traina T A; Poggesi I; Robson M; Asnis A; Duncan B A; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler M N
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Breast cancer research and treatment 2008;111(2):377-88.
2008: Dang Chau; Norton Larry; Hudis Clifford
Dose-dense chemotherapy with trastuzumab is an appropriate option.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3655-6; author reply 3656.
2008: Polite Blase N; Cirrincione Constance; Fleming Gini F; Berry Donald A; Seidman Andrew; Muss Hyman; Norton Larry; Shapiro Charles; Bakri Kamal; Marcom Kelly; Lake Diana; Schwartz Joel H; Hudis Clifford; Winer Eric P
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2659-65.
2008: DiGiovanna Michael P; Stern David F; Edgerton Susan; Broadwater Gloria; Dressler Lynn G; Budman Daniel R; Henderson I Craig; Norton Larry; Liu Edison T; Muss Hyman B; Berry Donald A; Hayes Daniel F; Thor Ann D
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2364-72.
2008: Ingle J N; Tu D; Pater J L; Muss H B; Martino S; Robert N J; Piccart M J; Castiglione M; Shepherd L E; Pritchard K I; Livingston R B; Davidson N E; Norton L; Perez E A; Abrams J S; Cameron D A; Palmer M J; Goss P E
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):877-82.
2008: Liu Minetta C; Demetri George D; Berry Donald A; Norton Larry; Broadwater Gloria; Robert Nicholas J; Duggan David; Hayes Daniel F; Henderson I Craig; Lyss Alan; Hopkins Judith; Kaufman Peter A; Marcom P Kelly; Younger Jerry; Lin Nancy; Tkaczuk Katherine; Winer Eric P; Hudis Clifford A;
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Cancer treatment reviews 2008;34(3):223-30.
2008: Traina Tiffany A; Theodoulou Maria; Feigin Kimberly; Patil Sujata; Tan K Lee; Edwards Charles; Dugan Ute; Norton Larry; Hudis Clifford
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1797-802.
2008: Seidman Andrew D; Berry Donald; Cirrincione Constance; Harris Lyndsay; Muss Hyman; Marcom P Kelly; Gipson Grandella; Burstein Harold; Lake Diana; Shapiro Charles L; Ungaro Peter; Norton Larry; Winer Eric; Hudis Clifford
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1642-9.
2008: Goss Paul E; Ingle James N; Pater Joseph L; Martino Silvana; Robert Nicholas J; Muss Hyman B; Piccart Martine J; Castiglione Monica; Shepherd Lois E; Pritchard Kathleen I; Livingston Robert B; Davidson Nancy E; Norton Larry; Perez Edith A; Abrams Jeffrey S; Cameron David A; Palmer Michael J; Tu Dongsheng
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1948-55.
2008: Tan Lee K; Giri Dilip; Hummer Amanda J; Panageas Katherine S; Brogi Edi; Norton Larry; Hudis Clifford; Borgen Patrick I; Cody Hiram S
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1803-9.
2008: Morrogh Mary; Park Anna; Norton Larry; King Tari A
Changing indications for surgery in patients with stage IV breast cancer: a current perspective.
Cancer 2008;112(7):1445-54.
2008: Gold Bert; Kirchhoff Tomas; Stefanov Stefan; Lautenberger James; Viale Agnes; Garber Judy; Friedman Eitan; Narod Steven; Olshen Adam B; Gregersen Peter; Kosarin Kristi; Olsh Adam; Bergeron Julie; Ellis Nathan A; Klein Robert J; Clark Andrew G; Norton Larry; Dean Michael; Boyd Jeff; Offit Kenneth
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(11):4340-5.
2008: Dang Chau; Fornier Monica; Sugarman Steven; Troso-Sandoval Tiffany; Lake Diana; D'Andrea Gabriella; Seidman Andrew; Sklarin Nancy; Dickler Maura; Currie Violante; Gilewski Theresa; Moynahan Mary Ellen; Drullinsky Pamela; Robson Mark; Wasserheit-Leiblich Carolyn; Mills Nancy; Steingart Richard; Panageas Katherine; Norton Larry; Hudis Clifford
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1216-22.
2008: Kauff Noah D; Domchek Susan M; Friebel Tara M; Robson Mark E; Lee Johanna; Garber Judy E; Isaacs Claudine; Evans D Gareth; Lynch Henry; Eeles Rosalind A; Neuhausen Susan L; Daly Mary B; Matloff Ellen; Blum Joanne L; Sabbatini Paul; Barakat Richard R; Hudis Clifford; Norton Larry; Offit Kenneth; Rebbeck Timothy R
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1331-7.
2008: Chandarlapaty Sarat; Sawai Ayana; Ye Qing; Scott Anisa; Silinski Melanie; Huang Ken; Fadden Pat; Partdrige Jeff; Hall Steven; Steed Paul; Norton Larry; Rosen Neal; Solit David B
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):240-8.
2008: Norton Larry
Cancer stem cells, self-seeding, and decremented exponential growth: theoretical and clinical implications.
Breast disease 2008;29():27-36.
2008: Olshen Adam B; Gold Bert; Lohmueller Kirk E; Struewing Jeffery P; Satagopan Jaya; Stefanov Stefan A; Eskin Eleazar; Kirchhoff Tomas; Lautenberger James A; Klein Robert J; Friedman Eitan; Norton Larry; Ellis Nathan A; Viale Agnes; Lee Catherine S; Borgen Patrick I; Clark Andrew G; Offit Kenneth; Boyd Jeff
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping.
BMC genetics 2008;9():14.
2007: Modi Shanu; Stopeck Alison T; Gordon Michael S; Mendelson David; Solit David B; Bagatell Rochelle; Ma Weining; Wheler Jennifer; Rosen Neal; Norton Larry; Cropp Gillian F; Johnson Robert G; Hannah Alison L; Hudis Clifford A
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5410-7.
2007: Norton Larry
Tumor dormancy: separating observations from experimental science.
Nature clinical practice. Oncology 2007;4(12):671.
2007: Harris Lyndsay; Fritsche Herbert; Mennel Robert; Norton Larry; Ravdin Peter; Taube Sheila; Somerfield Mark R; Hayes Daniel F; Bast Robert C;
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5287-312.
2007: Orlandi Francesca; Venanzi Franco M; Concetti Antonio; Yamauchi Hanako; Tiwari Shakuntala; Norton Larry; Wolchok Jedd D; Houghton Alan N; Gregor Polly D
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6195-203.
2007: Hayes Daniel F; Thor Ann D; Dressler Lynn G; Weaver Donald; Edgerton Susan; Cowan David; Broadwater Gloria; Goldstein Lori J; Martino Silvana; Ingle James N; Henderson I Craig; Norton Larry; Winer Eric P; Hudis Clifford A; Ellis Matthew J; Berry Donald A;
HER2 and response to paclitaxel in node-positive breast cancer.
The New England journal of medicine 2007;357(15):1496-506.
2007: King Tari A; Li Weiwei; Brogi Edi; Yee Cindy J; Gemignani Mary L; Olvera Narciso; Levine Douglas A; Norton Larry; Robson Mark E; Offit Kenneth; Borgen Patrick I; Boyd Jeff
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
Annals of surgical oncology 2007;14(9):2510-8.
2007: Muss Hyman B; Berry Donald A; Cirrincione Constance; Budman Daniel R; Henderson I Craig; Citron Marc L; Norton Larry; Winer Eric P; Hudis Clifford A;
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3699-704.
2007: Gilewski Teresa A; Ragupathi Govind; Dickler Maura; Powell Shemeeakah; Bhuta Sonal; Panageas Kathy; Koganty R Rao; Chin-Eng Jeannette; Hudis Clifford; Norton Larry; Houghton Alan N; Livingston Philip O
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2977-85.
2007: Goss Paul E; Ingle James N; Martino Silvana; Robert Nicholas J; Muss Hyman B; Piccart Martine J; Castiglione Monica; Tu Dongsheng; Shepherd Lois E; Pritchard Kathleen I; Livingston Robert B; Davidson Nancy E; Norton Larry; Perez Edith A; Abrams Jeffrey S; Cameron David A; Palmer Michael J; Pater Joseph L;
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2006-11.
2007: Piccart Martine; Goldhirsch Aron; Wood William; Pritchard Kathleen; Baselga José; Reaby Linda; Kössler Ingrid; Kyriakides Stella; Norton Larry; Coates Alan
Keeping faith with trial volunteers.
Nature 2007;446(7132):137-8.
2007: Fornier Monica N; Seidman Andrew D; Lake Diana; D'Andrea Gabriella; Bromberg Jacqueline; Robson Mark; Van Poznak Catherine; Panageas Katherine S; Atienza Marietta; Norton Larry; Hudis Clifford
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):223-7.
2006: Hicks James; Krasnitz Alexander; Lakshmi B; Navin Nicholas E; Riggs Michael; Leibu Evan; Esposito Diane; Alexander Joan; Troge Jen; Grubor Vladimir; Yoon Seungtai; Wigler Michael; Ye Kenny; Børresen-Dale Anne-Lise; Naume Bjørn; Schlicting Ellen; Norton Larry; Hägerström Torsten; Skoog Lambert; Auer Gert; Månér Susanne; Lundin Pär; Zetterberg Anders
Novel patterns of genome rearrangement and their association with survival in breast cancer.
Genome research 2006;16(12):1465-79.
2006: Rincon Mercedes; Broadwater Gloria; Harris Lyndsay; Crocker Abigail; Weaver Donald; Dressler Lynn; Berry Donald; Sutton Linda; Michaelson Richard; Messino Michael; Kirshner Jeffrey; Fleming Gini; Winer Eric; Hudis Clifford; Appel Stacy; Norton Larry; Muss Hyman;
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Breast cancer research and treatment 2006;100(3):301-8.
2006: Traina Tiffany A; Norton Larry; Drucker Karen; Singh Buvanesh
Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
The oncologist 2006;11(10):1070-1.
2006: Hurria Arti; Fleming Mark T; Baker Sharyn D; Kelly Wm Kevin; Cutchall Katie; Panageas Katherine; Caravelli James; Yeung Henry; Kris Mark G; Gomez Jorge; Miller Vincent A; D'Andrea Gabriella; Scher Howard I; Norton Larry; Hudis Clifford
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
2006: Ingle James N; Tu Dongsheng; Pater Joseph L; Martino Silvana; Robert Nicholas J; Muss Hyman B; Piccart Martine J; Castiglione Monica; Shepherd Lois E; Pritchard Kathleen I; Livingston Robert B; Davidson Nancy E; Norton Larry; Perez Edith A; Abrams Jeffrey S; Cameron David A; Palmer Michael J; Goss Paul E
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Breast cancer research and treatment 2006;99(3):295-300.
2006: Modi Shanu; D'Andrea Gabriella; Norton Larry; Yao Tzy Jyun; Caravelli James; Rosen Peter P; Hudis Clifford; Seidman Andrew D
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Clinical breast cancer 2006;7(3):270-7.
2006: Simon Richard; Norton Larry
The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
Nature clinical practice. Oncology 2006;3(8):406-7.
2006: Norton Larry; Massagué Joan
Is cancer a disease of self-seeding?
Nature medicine 2006;12(8):875-8.
2006: Hurria Arti; Goldfarb Shari; Rosen Carol; Holland Jimmie; Zuckerman Enid; Lachs Mark S; Witmer Matthew; van Gorp Wilfred G; Fornier Monica; D'Andrea Gabriella; Moasser Mark; Dang Chau; Van Poznak Catherine; Robson Mark; Currie Violante E; Theodoulou Maria; Norton Larry; Hudis Clifford
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
Breast cancer research and treatment 2006;98(3):343-8.
2006: Berry Donald A; Cirrincione Constance; Henderson I Craig; Citron Marc L; Budman Daniel R; Goldstein Lori J; Martino Silvana; Perez Edith A; Muss Hyman B; Norton Larry; Hudis Clifford; Winer Eric P
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
JAMA : the journal of the American Medical Association 2006;295(14):1658-67.
2006: Norton Larry
Use of dose-dense chemotherapy in the management of breast cancer.
Clinical advances in hematology & oncology : H&O 2006;4(1):36-7.
2006: Van Poznak C; Cross S S; Saggese M; Hudis C; Panageas K S; Norton L; Coleman R E; Holen I
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Journal of clinical pathology 2006;59(1):56-63.
2006: Ellis Nathan A; Kirchhoff Tomas; Mitra Nandita; Ye Tian-Zhang; Chuai Shaokun; Huang Helen; Nafa Khedoudja; Norton Larry; Neuhausen Susan; Gordon Derek; Struewing Jeffery P; Narod Steven; Offit Kenneth
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.
Genetic epidemiology 2006;30(1):48-61.
2005: Norton Larry
Society for Integrative Oncology First International Conference, New York City, November 2004. Keynote address.
Journal of the Society for Integrative Oncology 2005;3(4):121-3.
2005: Tornos Carmen; Soslow Robert; Chen Shirley; Akram Muzaffar; Hummer Amanda J; Abu-Rustum Nadeen; Norton Larry; Tan Lee K
Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
The American journal of surgical pathology 2005;29(11):1482-9.
2005: Fornier Monica N; Modi Shanu; Panageas Katherine S; Norton Larry; Hudis Clifford
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Cancer 2005;104(8):1575-9.
2005: Kauff Noah D; Mitra Nandita; Robson Mark E; Hurley Karen E; Chuai Shaokun; Goldfrank Deborah; Wadsworth Eve; Lee Johanna; Cigler Tessa; Borgen Patrick I; Norton Larry; Barakat Richard R; Offit Kenneth
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Journal of the National Cancer Institute 2005;97(18):1382-4.
2005: Beal Kathryn; Hudis Clifford; Norton Larry; Wagman Raquel; McCormick Beryl
Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
The breast journal 2005;11(5):317-20.
2005: Goss Paul E; Ingle James N; Martino Silvana; Robert Nicholas J; Muss Hyman B; Piccart Martine J; Castiglione Monica; Tu Dongsheng; Shepherd Lois E; Pritchard Kathleen I; Livingston Robert B; Davidson Nancy E; Norton Larry; Perez Edith A; Abrams Jeffrey S; Cameron David A; Palmer Michael J; Pater Joseph L
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Journal of the National Cancer Institute 2005;97(17):1262-71.
2005: Dressler Lynn G; Berry Donald A; Broadwater Gloria; Cowan David; Cox Kelly; Griffin Stephanie; Miller Ashley; Tse Jessica; Novotny Debra; Persons Diane L; Barcos Maurice; Henderson I Craig; Liu Edison T; Thor Ann; Budman Dan; Muss Hy; Norton Larry; Hayes Daniel F
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(19):4287-97.
2005: Hurria Arti; Brogan Kelly; Panageas Katherine S; Pearce Carol; Norton Larry; Jakubowski Ann; Zauderer Marjorie; Howard Jane; Hudis Clifford
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Breast cancer research and treatment 2005;92(2):151-6.
2005: Norton Larry
Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.
The oncologist 2005;10(6):370-81.
2005: Modi Shanu; Currie Violante E; Seidman Andrew D; Bach Ariadne M; Panageas Katherine S; Theodoulou Maria; Moasser Mark M; D'Andrea Gabriella M; Lake Diana E; Choi Jennifer; Norton Larry; Hudis Clifford A
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Clinical breast cancer 2005;6(1):55-60.
2005: Peters William P; Rosner Gary L; Vredenburgh James J; Shpall Elizabeth J; Crump Michael; Richardson Paul G; Schuster Michael W; Marks Lawrence B; Cirrincione Constance; Norton Larry; Henderson I C; Schilsky Richard L; Hurd David D
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2191-200.
2005: Modi Shanu; Seidman Andrew D; Dickler Maura; Moasser Mark; D'Andrea Gabriella; Moynahan Mary Ellen; Menell Jennifer; Panageas Katherine S; Tan Lee K; Norton Larry; Hudis Clifford A
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Breast cancer research and treatment 2005;90(2):157-63.
2005: Muss Hyman B; Woolf Susan; Berry Donald; Cirrincione Constance; Weiss Raymond B; Budman Daniel; Wood William C; Henderson I Craig; Hudis Clifford; Winer Eric; Cohen Harvey; Wheeler Judith; Norton Larry;
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
JAMA : the journal of the American Medical Association 2005;293(9):1073-81.
2005: Fornier M N; Seidman A D; Schwartz M K; Ghani F; Thiel R; Norton L; Hudis C
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(2):234-9.
2005: Seidman Andrew D; Norton Larry
Two regimens of docetaxel for metastatic breast cancer.
Current oncology reports 2005;7(1):7.
2005: Robson Mark; Svahn Tiffany; McCormick Beryl; Borgen Patrick; Hudis Clifford A; Norton Larry; Offit Kenneth
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Cancer 2005;103(1):44-51.
2005: Sartor Carolyn I; Peterson Bercedis L; Woolf Susan; Fitzgerald Thomas J; Laurie Frances; Turrisi Andrew J; Bogart Jeff; Henderson I Craig; Norton Larry
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):30-40.
2005: Modi Shanu; DiGiovanna Michael P; Lu Zhao; Moskowitz Chaya; Panageas Katherine S; Van Poznak Catherine; Hudis Clifford A; Norton Larry; Tan Lee; Stern David F; Carter Darryl; Seidman Andrew D
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Cancer investigation 2005;23(6):483-7.
2005: Hurria Arti; Hurria Anju; Brogan Kelly; Panageas Katherine S; Pearce Carol; Norton Larry; Jakubowski Ann; Howard Jane; Hudis Clifford
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
Drugs & aging 2005;22(9):785-91.
2005: Hurria Arti; Brogan Kelly; Panageas Katherine S; Jakubowski Ann; Zauderer Marjorie; Pearce Carol; Norton Larry; Howard Jane; Hudis Clifford
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Drugs & aging 2005;22(8):709-15.
2005: Fornier Monica; Norton Larry
Dose-dense adjuvant chemotherapy for primary breast cancer.
Breast cancer research : BCR 2005;7(2):64-9.
2004: Kattan Michael W; Giri Dilip; Panageas Katherine S; Hummer Amanda; Cranor Milicent; Van Zee Kimberly J; Hudis Clifford A; Norton Larry; Borgen Patrick I; Tan Lee K
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.
Cancer 2004;101(11):2509-15.
2004: Portlock C S; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz A D; O'Brien J P; Moskowitz C; Norton L; Yahalom J; Straus D J; Bertino J R
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(10):1495-503.
2004: Dang Chau T; D'Andrea Gabriella M; Moynahan Mary E; Dickler Maura N; Seidman Andrew D; Fornier Monica; Robson Mark E; Theodoulou Maria; Lake Diana; Currie Violante E; Hurria Arti; Panageas Katherine S; Norton Larry; Hudis Clifford A
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5754-61.
2004: Hughes Kevin S; Schnaper Lauren A; Berry Donald; Cirrincione Constance; McCormick Beryl; Shank Brenda; Wheeler Judith; Champion Lorraine A; Smith Thomas J; Smith Barbara L; Shapiro Charles; Muss Hyman B; Winer Eric; Hudis Clifford; Wood William; Sugarbaker David; Henderson I Craig; Norton Larry;
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
The New England journal of medicine 2004;351(10):971-7.
2004: King Tari A; Ganaraj Archana; Fey Jane V; Tan Lee K; Hudis Clifford; Norton Larry; Cody Hiram S; Borgen Patrick I
Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy.
Cancer 2004;101(5):926-33.
2004: Dang Chau T; Dannenberg Andrew J; Subbaramaiah Kotha; Dickler Maura N; Moasser Mark M; Seidman Andrew D; D'Andrea Gabriella M; Theodoulou Maria; Panageas Katherine S; Norton Larry; Hudis Clifford A
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4062-7.
2004: Winer Eric P; Berry Donald A; Woolf Susan; Duggan David; Kornblith Alice; Harris Lyndsay N; Michaelson Richard A; Kirshner Jeffrey A; Fleming Gini F; Perry Michael C; Graham Mark L; Sharp Stewart A; Keresztes Roger; Henderson I Craig; Hudis Clifford; Muss Hyman; Norton Larry
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2061-8.
2004: Kimmick Gretchen; Ratain Mark J; Berry Don; Woolf Susan; Norton Larry; Muss Hyman B;
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
Investigational new drugs 2004;22(1):83-9.
2004: Robson Mark E; Chappuis Pierre O; Satagopan Jaya; Wong Nora; Boyd Jeff; Goffin John R; Hudis Clifford; Roberge David; Norton Larry; Bégin Louis R; Offit Kenneth; Foulkes William D
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Breast cancer research : BCR 2004;6(1):R8-R17.
2003: Goss Paul E; Ingle James N; Martino Silvana; Robert Nicholas J; Muss Hyman B; Piccart Martine J; Castiglione Monica; Tu Dongsheng; Shepherd Lois E; Pritchard Kathleen I; Livingston Robert B; Davidson Nancy E; Norton Larry; Perez Edith A; Abrams Jeffrey S; Therasse Patrick; Palmer Michael J; Pater Joseph L
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
The New England journal of medicine 2003;349(19):1793-802.
2003: Offit Kenneth; Levran Orna; Mullaney Brian; Mah Katherine; Nafa Khedoudja; Batish Sat Dev; Diotti Raffaella; Schneider Hildegard; Deffenbaugh Amie; Scholl Thomas; Proud Virginia K; Robson Mark; Norton Larry; Ellis Nathan; Hanenberg Helmut; Auerbach Arleen D
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
Journal of the National Cancer Institute 2003;95(20):1548-51.
2003: Lucito Robert; Healy John; Alexander Joan; Reiner Andrew; Esposito Diane; Chi Maoyen; Rodgers Linda; Brady Amy; Sebat Jonathan; Troge Jennifer; West Joseph A; Rostan Seth; Nguyen Ken C Q; Powers Scott; Ye Kenneth Q; Olshen Adam; Venkatraman Ennapadam; Norton Larry; Wigler Michael
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation.
Genome research 2003;13(10):2291-305.
2003: Hurria Arti; Leung Denis; Trainor Kathleen; Norton Larry; Hudis Clifford
Screening chest imaging studies are not effective in the follow-up of breast cancer patients.
The Journal of oncology management : the official journal of the American College of Oncology Administrators 2003;12(5):13-5.
2003: Kornblith Alice B; Herndon James E; Weiss Raymond B; Zhang Chunfeng; Zuckerman Enid L; Rosenberg Sylvia; Mertz Magriet; Payne David; Jane Massie Mary; Holland James F; Wingate Patti; Norton Larry; Holland Jimmie C
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.
Cancer 2003;98(4):679-89.
2003: Weiss Raymond B; Woolf Susan H; Demakos Erin; Holland James F; Berry Donald A; Falkson Geoffrey; Cirrincione Constance T; Robbins Alice; Bothun Sandra; Henderson I Craig; Norton Larry;
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1825-35.
2003: Parnes H L; Cirrincione C; Aisner J; Berry D A; Allen S L; Abrams J; Chuang E; Cooper M R; Perry M C; Duggan D B; Szatrowski T P; Henderson I C; Norton L;
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1819-24.
2003: Hurria Arti; Leung Denis; Trainor Kathleen; Borgen Patrick; Norton Larry; Hudis Clifford
Factors influencing treatment patterns of breast cancer patients age 75 and older.
Critical reviews in oncology/hematology 2003;46(2):121-6.
2003: Citron Marc L; Berry Donald A; Cirrincione Constance; Hudis Clifford; Winer Eric P; Gradishar William J; Davidson Nancy E; Martino Silvana; Livingston Robert; Ingle James N; Perez Edith A; Carpenter John; Hurd David; Holland James F; Smith Barbara L; Sartor Carolyn I; Leung Eleanor H; Abrams Jeffrey; Schilsky Richard L; Muss Hyman B; Norton Larry
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1431-9.
2003: Henderson I Craig; Berry Donald A; Demetri George D; Cirrincione Constance T; Goldstein Lori J; Martino Silvana; Ingle James N; Cooper M Robert; Hayes Daniel F; Tkaczuk Katherine H; Fleming Gini; Holland James F; Duggan David B; Carpenter John T; Frei Emil; Schilsky Richard L; Wood William C; Muss Hyman B; Norton Larry
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):976-83.
2002: Modi Shanu; Panageas Katherine S; Duck Elaine T; Bach Ariadne; Weinstock Nancy; Dougherty James; Cramer Laura; Hudis Clifford; Norton Larry; Seidman Andrew
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3665-73.
2002: Baselga Jose; Norton Larry
Focus on breast cancer.
Cancer cell 2002;1(4):319-22.
2002: Kauff Noah D; Satagopan Jaya M; Robson Mark E; Scheuer Lauren; Hensley Martee; Hudis Clifford A; Ellis Nathan A; Boyd Jeff; Borgen Patrick I; Barakat Richard R; Norton Larry; Castiel Mercedes; Nafa Khedoudja; Offit Kenneth
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
The New England journal of medicine 2002;346(21):1609-15.
2002: Van Poznak Catherine; Tan Lee; Panageas Katherine S; Arroyo Crispinita D; Hudis Clifford; Norton Larry; Seidman Andrew D
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2319-26.
2002: Subbaramaiah Kotha; Norton Larry; Gerald William; Dannenberg Andrew J
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.
The Journal of biological chemistry 2002;277(21):18649-57.
2002: Scheuer Lauren; Kauff Noah; Robson Mark; Kelly Bridget; Barakat Richard; Satagopan Jaya; Ellis Nathan; Hensley Martee; Boyd Jeff; Borgen Patrick; Norton Larry; Offit Kenneth
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1260-8.
2002: Berry Donald A; Broadwater Gloria; Klein John P; Antman Karen; Aisner Joseph; Bitran Jacob; Costanza Mary; Freytes Cesar O; Stadtmauer Edward; Gale Robert Peter; Henderson I Craig; Lazarus Hillard M; McCarthy Philip L; Norton Larry; Parnes Howard; Pecora Andrew; Perry Michael C; Rowlings Philip; Spitzer Gary; Horowitz Mary M
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):743-50.
2002: Guidi Anthony J; Berry Donald A; Broadwater Gloria; Helmchen Birgit; Bleiweiss Ira J; Budman Daniel R; Henderson I Craig; Norton Larry; Hayes Daniel F
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):732-42.
2001: Dickler M N; Norton L
The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Annals of the New York Academy of Sciences 2001;949():134-42.
2001: Fornier M N; Seidman A D; Theodoulou M; Moynahan M E; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas K S; Norton L; Hudis C
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3934-41.
2001: Hayes D F; Yamauchi H; Broadwater G; Cirrincione C T; Rodrigue S P; Berry D A; Younger J; Panasci L L; Millard F; Duggan D B; Norton L; Henderson I C;
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2703-11.
2001: Münster P N; Basso A; Solit D; Norton L; Rosen N
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2228-36.
2001: Norton L
High-dose chemotherapy for breast cancer: "how do you know?".
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2769-70.
2001: Seidman A D; Fornier M N; Esteva F J; Tan L; Kaptain S; Bach A; Panageas K S; Arroyo C; Valero V; Currie V; Gilewski T; Theodoulou M; Moynahan M E; Moasser M; Sklarin N; Dickler M; D'Andrea G; Cristofanilli M; Rivera E; Hortobagyi G N; Norton L; Hudis C A
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2587-95.
2001: Van Poznak C; Seidman A D; Reidenberg M M; Moasser M M; Sklarin N; Van Zee K; Borgen P; Gollub M; Bacotti D; Yao T J; Bloch R; Ligueros M; Sonenberg M; Norton L; Hudis C
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
Breast cancer research and treatment 2001;66(3):239-48.
2001: Münster P N; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman A; Booser D; Theriault R; Norton L; Hudis C
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2002-9.
2001: Slamon D J; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
The New England journal of medicine 2001;344(11):783-92.
2001: Gilewski T; Ragupathi G; Bhuta S; Williams L J; Musselli C; Zhang X F; Bornmann W G; Spassova M; Bencsath K P; Panageas K S; Chin J; Hudis C A; Norton L; Houghton A N; Livingston P O; Danishefsky S J
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(6):3270-5.
2001: Cauley J A; Norton L; Lippman M E; Eckert S; Krueger K A; Purdie D W; Farrerons J; Karasik A; Mellstrom D; Ng K W; Stepan J J; Powles T J; Morrow M; Costa A; Silfen S L; Walls E L; Schmitt H; Muchmore D B; Jordan V C; Ste-Marie L G
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Breast cancer research and treatment 2001;65(2):125-34.
2001: Kornblith A B; Herndon J E; Zuckerman E; Viscoli C M; Horwitz R I; Cooper M R; Harris L; Tkaczuk K H; Perry M C; Budman D; Norton L C; Holland J;
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.
Cancer 2001;91(2):443-54.
2001: Norton L
Dose-intensity, dose-escalation, and dose-density in the adjuvant chemotherapy of primary, operable breast cancer.
Breast disease 2001;14():81-9.
2001: Munster P N; Norton L
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.
Breast cancer research : BCR 2001;3(6):361-4.
2001: Norton L
Theoretical concepts and the emerging role of taxanes in adjuvant therapy.
The oncologist 2001;6 Suppl 3():30-5.
2000: Lucito R; West J; Reiner A; Alexander J; Esposito D; Mishra B; Powers S; Norton L; Wigler M
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations.
Genome research 2000;10(11):1726-36.
2000: Berry D A; Muss H B; Thor A D; Dressler L; Liu E T; Broadwater G; Budman D R; Henderson I C; Barcos M; Hayes D; Norton L
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3471-9.
2000: Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao T J; Panageas K; Moynahan M; Houghton A; Norton L; Livingston P O
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1693-701.
2000: Subbaramaiah K; Hart J C; Norton L; Dannenberg A J
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways.
The Journal of biological chemistry 2000;275(20):14838-45.
2000: Guidi A J; Berry D A; Broadwater G; Perloff M; Norton L; Barcos M P; Hayes D F
Association of angiogenesis in lymph node metastases with outcome of breast cancer.
Journal of the National Cancer Institute 2000;92(6):486-92.
2000: Hazan R B; Phillips G R; Qiao R F; Norton L; Aaronson S A
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis.
The Journal of cell biology 2000;148(4):779-90.
2000: Baselga J; Pfister D; Cooper M R; Cohen R; Burtness B; Bos M; D'Andrea G; Seidman A; Norton L; Gunnett K; Falcey J; Anderson V; Waksal H; Mendelsohn J
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):904-14.
2000: Donnelly J M; Kornblith A B; Fleishman S; Zuckerman E; Raptis G; Hudis C A; Hamilton N; Payne D; Massie M J; Norton L; Holland J C
A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners.
Psycho-oncology 2000;9(1):44-56.
2000: Gilewski T; Seidman A; Norton L; Hudis C
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S23-6.
1999: Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Journal of the National Cancer Institute 1999;91(24):2112-7.
1999: Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz C C; Dantis L; Sklarin N T; Seidman A D; Hudis C A; Moore J; Rosen P P; Twaddell T; Henderson I C; Norton L
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Seminars in oncology 1999;26(4 Suppl 12):78-83.
1999: Cummings S R; Eckert S; Krueger K A; Grady D; Powles T J; Cauley J A; Norton L; Nickelsen T; Bjarnason N H; Morrow M; Lippman M E; Black D; Glusman J E; Costa A; Jordan V C
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA : the journal of the American Medical Association 1999;281(23):2189-97.
1999: Levine E G; Cirrincione C T; Szatrowski T P; Canellos G; Norton L; Henderson I C
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.
American journal of clinical oncology 1999;22(3):218-22.
1999: Costanza M E; Weiss R B; Henderson I C; Norton L; Berry D A; Cirrincione C; Winer E; Wood W C; Frei E; McIntyre O R; Schilsky R L
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1397-406.
1999: Hudis C; Fornier M; Riccio L; Lebwohl D; Crown J; Gilewski T; Surbone A; Currie V; Seidman A; Reichman B; Moynahan M; Raptis G; Sklarin N; Theodoulou M; Weiselberg L; Salvaggio R; Panageas K S; Yao T J; Norton L
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1118.
1999: Norton L
Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
Seminars in oncology 1999;26(1 Suppl 3):1-4.
1999: Norton L
Kinetic concepts in the systemic drug therapy of breast cancer.
Seminars in oncology 1999;26(1 Suppl 2):11-20.
1999: D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan M E; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton M A; Yao T J; Seidman A D
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):275-9.
1999: Hudis C; Seidman A; Baselga J; Raptis G; Lebwohl D; Gilewski T; Moynahan M; Sklarin N; Fennelly D; Crown J P; Surbone A; Uhlenhopp M; Riedel E; Yao T J; Norton L
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):93-100.
1999: Abrams J; Aisner J; Cirrincione C; Berry D A; Muss H B; Cooper M R; Henderson I C; Panasci L; Kirshner J; Ellerton J; Norton L
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):64-73.
1998: Norton L
Breast cancer advocates in clinical research: a trialist's perspective.
Breast disease 1998;10(5-6):51-9.
1998: Seidman A D; Hudis C A; Albanell J; Tong W; Tepler I; Currie V; Moynahan M E; Theodoulou M; Gollub M; Baselga J; Norton L
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3353-61.
1998: Thor A D; Berry D A; Budman D R; Muss H B; Kute T; Henderson I C; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu E T
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Journal of the National Cancer Institute 1998;90(18):1346-60.
1998: Budman D R; Berry D A; Cirrincione C T; Henderson I C; Wood W C; Weiss R B; Ferree C R; Muss H B; Green M R; Norton L; Frei E
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
Journal of the National Cancer Institute 1998;90(16):1205-11.
1998: Baselga J; Norton L; Albanell J; Kim Y M; Mendelsohn J
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Cancer research 1998;58(13):2825-31.
1998: Harlap S; Zauber A G; Pollack D M; Tang J; Arena A E; Sternfels P; Borgen P; Norton L
Survival of premenopausal women with breast carcinoma: effects of menstrual timing of surgery.
Cancer 1998;83(1):76-88.
1998: Aghajanian C; Fennelly D; Shapiro F; Waltzman R; Almadrones L; O'Flaherty C; O'Conner K; Venkatraman E; Barakat R; Curtin J; Brown C; Reich L; Wuest D; Norton L; Hoskins W; Spriggs D R
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1852-60.
1998: Robson M; Gilewski T; Haas B; Levin D; Borgen P; Rajan P; Hirschaut Y; Pressman P; Rosen P P; Lesser M L; Norton L; Offit K
BRCA-associated breast cancer in young women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1642-9.
1998: Robson M; Rajan P; Rosen P P; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Cancer research 1998;58(9):1839-42.
1998: Hazan R B; Norton L
The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton.
The Journal of biological chemistry 1998;273(15):9078-84.
1998: Hudis C; Riccio L; Seidman A; Baselga J; Currie V; Fennelly D; Gilewski T; Lebwohl D; Moynahan M; Raptis G; Surbone A; Sklarin N; Yao T J; Keefe D; Norton L
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Cancer investigation 1998;16(2):67-71.
1997: Hudis C; Riccio L; Holmes F; Seidman A; Baselga J; Currie V; Fennelly D; Gilewski T; Moynahan M; Raptis G; Sklarin N; Surbone A; Uhlenhopp M; Maickel N; Yao T J; Hellmann S; Usakewicz J; Hortobagyi G; Norton L
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(13):2198-202.
1997: Seidman A D; Hudis C A; McCaffrey J; Tong W; Currie V; Moynahan M E; Theodoulou M; Tepler I; Gollub M; Norton L
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-72-S17-76.
1997: Norton L
Conceptual basis for advances in the systemic drug therapy of breast cancer.
Seminars in oncology 1997;24(4 Suppl 11):S11-2-S11-12.
1997: Norton L
Evolving concepts in the systemic drug therapy of breast cancer.
Seminars in oncology 1997;24(4 Suppl 10):S10-3-S10-10.
1997: Norton L; Piccart M J
Innovative approaches to the treatment of advanced breast cancer: introduction.
Seminars in oncology 1997;24(4 Suppl 10):S10-1-S10-2.
1997: Norton L W
A stereotactic stand-off.
American journal of surgery 1997;173(3):151-2.
1997: Baselga J; Seidman A D; Rosen P P; Norton L
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):43-8.
1997: Seidman A D; Hudis C A; Raptis G; Baselga J; Fennelly D; Norton L
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):20-8.
1997: Norton L
Truth, science, and the oncologist.
Annals of the New York Academy of Sciences 1997;809():66-71.
1997: Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):187-92.
1997: Robson M; Dabney M K; Rosenthal G; Ludwig S; Seltzer M H; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Genetic testing 1997;1(1):47-51.
1996: Tonin P; Weber B; Offit K; Couch F; Rebbeck T R; Neuhausen S; Godwin A K; Daly M; Wagner-Costalos J; Berman D; Grana G; Fox E; Kane M F; Kolodner R D; Krainer M; Haber D A; Struewing J P; Warner E; Rosen B; Lerman C; Peshkin B; Norton L; Serova O; Foulkes W D; Garber J E
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.
Nature medicine 1996;2(11):1179-83.
1996: Oddoux C; Struewing J P; Clayton C M; Neuhausen S; Brody L C; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Nature genetics 1996;14(2):188-90.
1996: Hayes D F; Bast R C; Desch C E; Fritsche H; Kemeny N E; Jessup J M; Locker G Y; Macdonald J S; Mennel R G; Norton L; Ravdin P; Taube S; Winn R J
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
Journal of the National Cancer Institute 1996;88(20):1456-66.
1996: Norton L
Management of advanced breast cancer: patient needs, challenges and new treatment options. Introduction.
Anti-cancer drugs 1996;7 Suppl 2():1-3.
1996: Hudis C A; Norton L
Adjuvant drug therapy for operable breast cancer.
Seminars in oncology 1996;23(4):475-93.
1996: Seidman A D; Hochhauser D; Gollub M; Edelman B; Yao T J; Hudis C A; Francis P; Fennelly D; Gilewski T A; Moynahan M E; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1877-84.
1996: Offit K; Gilewski T; McGuire P; Schluger A; Hampel H; Brown K; Swensen J; Neuhausen S; Skolnick M; Norton L; Goldgar D
Germline BRCA1 185delAG mutations in Jewish women with breast cancer.
Lancet 1996;347(9016):1643-5.
1996: Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Nature genetics 1996;13(1):126-8.
1996: Tross S; Herndon J; Korzun A; Kornblith A B; Cella D F; Holland J F; Raich P; Johnson A; Kiang D T; Perloff M; Norton L; Wood W; Holland J C
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.
Journal of the National Cancer Institute 1996;88(10):661-7.
1996: Perloff M; Norton L; Korzun A H; Wood W C; Carey R W; Gottlieb A; Aust J C; Bank A; Silver R T; Saleh F; Canellos G P; Perry M C; Weiss R B; Holland J F
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1589-98.
1996: Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz C C; Dantis L; Sklarin N T; Seidman A D; Hudis C A; Moore J; Rosen P P; Twaddell T; Henderson I C; Norton L
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):737-44.
1996: Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1996;23(1 Suppl 1):58-64.
1996: McCormick B; Norton L; Yao T J; Yahalom J; Petrek J A
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery.
The cancer journal from Scientific American 1996;2(1):39-45.
1996: Hudis C A; Seidman A D; Crown J P; Balmaceda C; Freilich R; Gilewski T A; Hakes T B; Currie V; Lebwohl D E; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):58-65.
1996: Bose S; Lesser M L; Norton L; Rosen P P
Immunophenotype of intraductal carcinoma.
Archives of pathology & laboratory medicine 1996;120(1):81-5.
1995: Crown J; Raptis G; Hamilton N; Hudis C; Vahclat L; Fennelly D; Norton L
High-dose chemotherapy of breast cancer.
The Canadian journal of oncology 1995;5 Suppl 1():80-2.
1995: Leonard C E; Wood M E; Zhen B; Rankin J; Waitz D A; Norton L; Howell K; Sedlacek S
Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2906-15.
1995: Youngson B J; Anelli A; Van Zee K J; Borgen P I; Norton L; Rosen P P
Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.
The American journal of surgical pathology 1995;19(12):1354-8.
1995: Norton L; Rosen P P; Rosen N
Refining the origins of breast cancer.
Nature medicine 1995;1(12):1250-1.
1995: Seidman A D; Hudis C A; Fennelly D; Raptis G; Baselga J; Norton L
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.
Seminars in oncology 1995;22(5 Suppl 12):108-16.
1995: DiLorenzo T A; Jacobsen P B; Bovbjerg D H; Chang H; Hudis C A; Sklarin N T; Norton L
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):705-11.
1995: Seidman A D; Hudis C A; Norton L
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Seminars in oncology 1995;22(4 Suppl 8):3-8.
1995: Rosen P P; Lesser M L; Arroyo C D; Cranor M; Borgen P; Norton L
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(4):821-30.
1995: Fennelly D W; Norton L; Sznol M; Hakes T B
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer.
Cancer 1995;75(8):2099-102.
1995: Crown J; Hamilton N; Raptis G; Kritz A; Vahdat L; Norton L
Carboplatin and etoposide in metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(4):403.
1995: Rosen P P; Lesser M L; Arroyo C D; Cranor M; Borgen P; Norton L
Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.
Cancer 1995;75(6):1320-6.
1995: Jacobsen P B; Bovbjerg D H; Schwartz M D; Hudis C A; Gilewski T A; Norton L
Conditioned emotional distress in women receiving chemotherapy for breast cancer.
Journal of consulting and clinical psychology 1995;63(1):108-14.
1995: Leonard C; Corkill M; Tompkin J; Zhen B; Waitz D; Norton L; Kinzie J
Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):47-53.
1995: Crown J; Norton L
Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 4():21-6.
1995: Crown J; Raptis G; Hamilton N; Fennelly D; Vahdat L; Norton L
High-dose chemotherapy of breast cancer: current status and developmental strategies.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):809-11.
1994: Schneider J G; Crown J P; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore M A
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
Bone marrow transplantation 1994;14(6):877-84.
1994: Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao T J; Markman M; Norton L; Crown J
Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Cancer research 1994;54(23):6137-42.
1994: Shapiro F; Yao T J; Raptis G; Reich L; Norton L; Moore M A
Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer.
Blood 1994;84(10):3567-74.
1994: Seidman A D; Norton L; Reichman B S; Crown J P; Yao T J; Hakes T B; Lebwohl D E; Gilewski T A; Hudis C A; Surbone A
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Oncology 1994;51 Suppl 1():33-9.
1994: Norton L
Salvage chemotherapy of breast cancer.
Seminars in oncology 1994;21(4 Suppl 7):19-24.
1994: Portenoy R K; Thaler H T; Kornblith A B; Lepore J M; Friedlander-Klar H; Coyle N; Smart-Curley T; Kemeny N; Norton L; Hoskins W
Symptom prevalence, characteristics and distress in a cancer population.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1994;3(3):183-9.
1994: Wood W C; Budman D R; Korzun A H; Cooper M R; Younger J; Hart R D; Moore A; Ellerton J A; Norton L; Ferree C R
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
The New England journal of medicine 1994;330(18):1253-9.
1994: Armas O A; Gerald W L; Lesser M L; Arroyo C D; Norton L; Rosen P P
Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma.
The American journal of surgical pathology 1994;18(2):158-66.
1994: Surbone A; Norton L
[Kinetics of breast neoplasms]
Minerva medica 1994;85(1-2):7-16.
1994: Holland J F; Bhardwaj S; Norton L
Re: "We may be lost, but we're sure makin' good time".
Cancer investigation 1994;12(2):270-2.
1994: Portenoy R K; Thaler H T; Kornblith A B; Lepore J M; Friedlander-Klar H; Kiyasu E; Sobel K; Coyle N; Kemeny N; Norton L
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1326-36.
1994: Foa R; Norton L; Seidman A D
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
International journal of clinical & laboratory research 1994;24(1):6-14.
1993: Leonard C; Harlow C L; Coffin C; Drose J; Norton L; Kinzie J
Use of ultrasound to guide radiation boost planning following lumpectomy for carcinoma of the breast.
International journal of radiation oncology, biology, physics 1993;27(5):1193-7.
1993: Hudis C A; Norton L
Systemic adjuvant therapy for breast cancer.
Current opinion in oncology 1993;5(6):982-90.
1993: Surbone A; Norton L
Kinetic concepts in the treatment of breast cancer.
Annals of the New York Academy of Sciences 1993;698():48-62.
1993: Jacobsen P B; Bovbjerg D H; Schwartz M D; Andrykowski M A; Futterman A D; Gilewski T; Norton L; Redd W H
Formation of food aversions in cancer patients receiving repeated infusions of chemotherapy.
Behaviour research and therapy 1993;31(8):739-48.
1993: Rosen P P; Groshen S; Kinne D W; Norton L
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2090-100.
1993: Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller W H; Mendelsohn J
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Journal of the National Cancer Institute 1993;85(16):1327-33.
1993: Lichtman S M; Ratain M J; Van Echo D A; Rosner G; Egorin M J; Budman D R; Vogelzang N J; Norton L; Schilsky R L
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Journal of the National Cancer Institute 1993;85(16):1319-26.
1993: Seidman A D; Norton L; Reichman B S; Crown J P; Yao T J; Heelan R; Hakes T B; Lebwohl D E; Gilewski T A; Surbone A
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.
Seminars in oncology 1993;20(4 Suppl 3):40-5.
1993: Yorke E D; Fuks Z; Norton L; Whitmore W; Ling C C
Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer.
Cancer research 1993;53(13):2987-93.
1993: McCormick B; Begg C B; Norton L; Yao T J; Kinne D
Timing of radiotherapy in the treatment of early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):191-3.
1993: Norton L
Kinetic concepts in the treatment of breast cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;127():1-6.
1993: Bhardwaj S; Holland J F; Norton L
An intensive sequenced adjuvant chemotherapy regimen for breast cancer.
Cancer investigation 1993;11(1):6-9.
1992: Bovbjerg D H; Redd W H; Jacobsen P B; Manne S L; Taylor K L; Surbone A; Crown J P; Norton L; Gilewski T A; Hudis C A
An experimental analysis of classically conditioned nausea during cancer chemotherapy.
Psychosomatic medicine 1992;54(6):623-37.
1992: Scher H I; Norton L
Chemotherapy for urothelial tract malignancies: breaking the deadlock.
Seminars in surgical oncology 1992;8(5):316-41.
1992: Norton L
Evolving concepts in the adjuvant systemic therapy of operable breast cancer.
Cancer treatment and research 1992;60():3-25.
1991: Norton L
Metastatic breast cancer. Length and quality of life.
The New England journal of medicine 1991;325(19):1370-1.
1991: Crown J; Norton L
Adjuvant systemic therapy for early breast cancer.
Seminars in surgical oncology 1991;7(5):283-90.
1991: Hayes D F; Mesa-Tejada R; Papsidero L D; Croghan G A; Korzun A H; Norton L; Wood W; Strauchen J A; Grimes M; Weiss R B
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1113-23.
1991: Norton L; Day R
Potential innovations in scheduling of cancer chemotherapy.
Important advances in oncology 1991;():57-72.
1991: Crown J; Lipzstein R; Cohen S; Goldsmith M; Wisch N; Paciucci P A; Silverman L; Weiner M; Jaffrey I; Norton L
Chemotherapy of metastatic Merkel cell cancer.
Cancer investigation 1991;9(2):129-32.
1991: Dawson N A; Costanza M E; Korzun A H; Clamon G H; Pollak M; Vogelzang N J; Carey R W; Norton L
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Medical and pediatric oncology 1991;19(4):283-8.
1990: Gottlieb A J; Anderson J R; Ginsberg S J; Bloomfield C D; Norton L; Barcos M; Peterson B A; Nissen N; Henderson E S; Holland J F
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Cancer 1990;66(9):1888-96.
1990: Ringenberg Q S; Propert K J; Muss H B; Weiss R B; Schilsky R L; Modeas C; Perry M C; Norton L; Green M
Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Investigational new drugs 1990;8(2):221-6.
1990: Norton L
Biology of residual breast cancer after therapy: a kinetic interpretation.
Progress in clinical and biological research 1990;354A():109-32.
1989: Wall J G; Weiss R B; Norton L; Perloff M; Rice M A; Korzun A H; Wood W C
Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study.
The American journal of medicine 1989;87(5):501-4.
1988: Norton L
A Gompertzian model of human breast cancer growth.
Cancer research 1988;48(24 Pt 1):7067-71.
1988: Norton L
Implications of growth kinetic concepts for cancer chemoprevention.
Cancer investigation 1988;6(5):625-8.
1987: Jones R B; Holland J F; Bhardwaj S; Norton L; Wilfinger C; Strashun A
A phase I-II study of intensive-dose adriamycin for advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(2):172-7.
1987: Ginsberg S J; Anderson J R; Gottlieb A J; Bloomfield C D; Norton L; Barcos M; Holland J F
A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851.
NCI monographs : a publication of the National Cancer Institute 1987;(5):77-80.
1986: Ellis M E; Weiss R B; Korzun A H; Rice M A; Norton L; Perloff M; Lesnick G J; Wood W C
Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study.
American journal of clinical oncology 1986;9(6):533-6.
1986: Norton L; Simon R
The Norton-Simon hypothesis revisited.
Cancer treatment reports 1986;70(1):163-9.
1985: Norton L
Implications of kinetic heterogeneity in clinical oncology.
Seminars in oncology 1985;12(3):231-49.
1984: Chahinian A P; Norton L; Holland J F; Szrajer L; Hart R D
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.
Cancer research 1984;44(4):1688-92.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Larry Norton

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Larry Norton (preview)

All Publications